Journal article
Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis
Leukemia & lymphoma, Vol.63(4), pp.939-945
03/21/2022
DOI: 10.1080/10428194.2021.2005046
PMID: 34789057
Abstract
Clinical trials do not routinely capture long-term overall survival (OS) in acute myeloid leukemia (AML). We utilized a large National Cancer Database (NCDB) to determine different factors affecting 10-year OS in AML. For patients, 18-59 years who were treated with chemotherapy only without upfront hematopoietic cell transplant (HCT), younger age, female, CBF AML, higher income, and private insurance conferred higher 10-year OS. Among patients, 18-59 years treated with chemotherapy and upfront HCT, younger age and private insurance conferred higher 10-year OS. In a Cox proportional hazard model, the likelihood of death decreased with younger age, fewer comorbidities, treatment at an academic center, private insurance, and use of multiagent chemotherapy. Our results demonstrate poor long-term OS even among younger patients and highlights disparities in leukemia care based on insurance type.
Details
- Title: Subtitle
- Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis
- Creators
- Nabin Khanal - Franciscan University of SteubenvilleValerie Shostrom - University of Nebraska Medical CenterPrajwal Dhakal - University of IowaShristi Upadhyay Banskota - University of Nebraska Medical CenterChakra Chaulagain - Cleveland Clinic FloridaFiona He - University of MinnesotaKailash Mosalpuria - Nebraska Hematology-OncologyKrishna Gundabolu - University of Nebraska Medical CenterVijaya Raj Bhatt - University of Nebraska Medical Center
- Resource Type
- Journal article
- Publication Details
- Leukemia & lymphoma, Vol.63(4), pp.939-945
- Publisher
- Taylor & Francis
- DOI
- 10.1080/10428194.2021.2005046
- PMID
- 34789057
- ISSN
- 1042-8194
- eISSN
- 1029-2403
- Grant note
- DOI: 10.13039/100008373, name: Takeda; DOI: 10.13039/100019510, name: Omeros; DOI: 10.13039/100016471, name: Agios; DOI: 10.13039/100006483, name: Abbvie; DOI: 10.13039/100004328, name: Genentech; name: Partner therapeutics; name: Rigel; DOI: 10.13039/100017655, name: Incyte; name: LLC; name: Jazz; DOI: 10.13039/100004319, name: Pfizer; name: Tolero Pharmaceuticals, Inc; name: National Marrow Donor Program
- Language
- English
- Date published
- 03/21/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359696602771
Metrics
8 Record Views